Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.
Total raised: $170M
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.12.2019 | Series C | $85M | - |
| 10.01.2019 | Series B | $85M | New Enterp... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 05.12.2019 | Black Diamond Therapeutics Raises $85M in Series C Financing | Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based precision oncology medicine company pione... | finsmes.co... |
| 10.01.2019 | NEA Co-Leads $85M Series B in Black Diamond Therapeutics | Black Diamond Therapeutics, Inc., a biotechnology company developing next-generation precision medic... | citybizlis... |
| 10.01.2019 | Black Diamond Therapeutics Closes $85M Series B Financing | Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing next-gen... | finsmes.co... |